WallStreetZenWallStreetZen

NASDAQ: SGMO
Sangamo Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for SGMO

Based on 2 analysts offering 12 month price targets for Sangamo Therapeutics Inc.
Min Forecast
$2.00+259.07%
Avg Forecast
$3.50+528.37%
Max Forecast
$5.00+797.67%

Should I buy or sell SGMO stock?

Based on 2 analysts offering ratings for Sangamo Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 50%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SGMO stock forecasts and price targets.

SGMO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-15
lockedlocked$00.00+00.00%2024-03-14

1 of 1

Forecast return on equity

Is SGMO forecast to generate an efficient return?
Company
-12.81%
Industry
75.86%
Market
79.52%
SGMO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SGMO forecast to generate an efficient return on assets?
Company
-5.63%
Industry
30.88%
SGMO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SGMO earnings per share forecast

What is SGMO's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
-$0.53
Avg 2 year Forecast
-$0.22
Avg 3 year Forecast
-$0.19

SGMO revenue forecast

What is SGMO's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$43.0M+129.19%
Avg 2 year Forecast
$94.7M+404.88%
Avg 3 year Forecast
$72.5M+286.39%
SGMO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SGMO revenue growth forecast

How is SGMO forecast to perform vs Biotechnology companies and vs the US market?
Company
65.35%
Industry
35.1%
Market
9.92%
SGMO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SGMO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SGMO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SGMO$0.56$3.50+528.37%Buy
FGEN$1.16N/AN/A
OMGA$2.10$10.00+376.19%Strong Buy
AMLX$1.68$5.20+209.52%Buy
GOSS$0.52$8.60+1,563.44%Strong Buy

Sangamo Therapeutics Stock Forecast FAQ

Is Sangamo Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: SGMO) stock is to Buy SGMO stock.

Out of 2 analysts, 0 (0%) are recommending SGMO as a Strong Buy, 1 (50%) are recommending SGMO as a Buy, 1 (50%) are recommending SGMO as a Hold, 0 (0%) are recommending SGMO as a Sell, and 0 (0%) are recommending SGMO as a Strong Sell.

If you're new to stock investing, here's how to buy Sangamo Therapeutics stock.

What is SGMO's earnings growth forecast for 2024-2026?

(NASDAQ: SGMO) Sangamo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.77%.

Sangamo Therapeutics's earnings in 2024 is -$328,053,000.On average, 5 Wall Street analysts forecast SGMO's earnings for 2024 to be -$110,810,381, with the lowest SGMO earnings forecast at -$159,782,759, and the highest SGMO earnings forecast at -$83,004,030. On average, 5 Wall Street analysts forecast SGMO's earnings for 2025 to be -$46,482,257, with the lowest SGMO earnings forecast at -$128,656,247, and the highest SGMO earnings forecast at $43,577,116.

In 2026, SGMO is forecast to generate -$39,945,690 in earnings, with the lowest earnings forecast at -$93,379,534 and the highest earnings forecast at -$2,075,101.

What is SGMO's revenue growth forecast for 2024-2026?

(NASDAQ: SGMO) Sangamo Therapeutics's forecast annual revenue growth rate of 65.35% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.1%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Sangamo Therapeutics's revenue in 2024 is $18,756,000.On average, 4 Wall Street analysts forecast SGMO's revenue for 2024 to be $8,920,235,637, with the lowest SGMO revenue forecast at $6,733,701,966, and the highest SGMO revenue forecast at $10,479,258,838. On average, 4 Wall Street analysts forecast SGMO's revenue for 2025 to be $19,650,166,647, with the lowest SGMO revenue forecast at $6,864,433,314, and the highest SGMO revenue forecast at $48,142,337,632.

In 2026, SGMO is forecast to generate $15,038,670,228 in revenue, with the lowest revenue forecast at $10,850,701,874 and the highest revenue forecast at $20,232,232,410.

What is SGMO's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: SGMO) forecast ROA is -5.63%, which is lower than the forecast US Biotechnology industry average of 30.88%.

What is SGMO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year SGMO price target, the average SGMO price target is $3.50, with the highest SGMO stock price forecast at $5.00 and the lowest SGMO stock price forecast at $2.00.

On average, Wall Street analysts predict that Sangamo Therapeutics's share price could reach $3.50 by May 15, 2025. The average Sangamo Therapeutics stock price prediction forecasts a potential upside of 528.37% from the current SGMO share price of $0.56.

What is SGMO's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: SGMO) Sangamo Therapeutics's current Earnings Per Share (EPS) is -$1.86. On average, analysts forecast that SGMO's EPS will be -$0.53 for 2024, with the lowest EPS forecast at -$0.77, and the highest EPS forecast at -$0.40. On average, analysts forecast that SGMO's EPS will be -$0.22 for 2025, with the lowest EPS forecast at -$0.62, and the highest EPS forecast at $0.21. In 2026, SGMO's EPS is forecast to hit -$0.19 (min: -$0.45, max: -$0.01).

What is SGMO's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: SGMO) forecast ROE is -12.81%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.